PathAI develops artificial intelligence-powered technology and an integrated platform for pathology aimed at improving diagnosis and treatment of diseases such as cancer. The company works with life sciences companies, researchers, pharmaceutical and diagnostic partners to advance precision medicine. PathAI plans to expand its product suite and commercial footprint to support the full lifecycle of drug development from translational research to global commercialization. It intends to develop AI-based pathology offerings for biopharma in disease indications beyond oncology and NASH. The company is also building a scalable workflow platform for CROs and reference lab partners to support broader deployments. PathAI emphasizes collaborations with pharmaceutical and diagnostic partners as part of its growth and product strategy. PathAI develops AI-powered technology and a platform intended to improve diagnostic accuracy and treatment efficacy for diseases such as cancer, using machine and deep learning. The company’s platform is applied to digital pathology and aims to advance pathology research and immuno-oncology development. With the new funding, PathAI plans to bolster and accelerate its clinical development capabilities and deepen partnerships with pharmaceutical companies. PathAI has worked strategically with industry partners to integrate insights from data into cancer therapy development. The company is headquartered in Boston and was founded in 2016. Including the latest financing, PathAI has raised a total of $90 million since its founding. PathAI is a Boston, MA-based provider of AI-powered technology for pathology research. Its platform uses machine and deep learning to improve diagnostic accuracy and treatment efficacy for diseases such as cancer. The company provides AI-powered research tools and services and works with leading life sciences companies and researchers to advance precision medicine. PathAI intends to use the funds from the LabCorp investment to expand clinical development of its AI-enabled computational pathology and to advance integration with clinical laboratories. The company is led by co-founder and CEO Andy Beck, M.D., Ph.D. Financially, LabCorp's strategic investment amount was not disclosed and follows a $60M round announced the prior month led by General Atlantic and General Catalyst. PathAI develops AI-powered technology and a flagship pathology research platform intended to improve the accuracy, reproducibility, and sub-typing of disease diagnoses such as cancer. The company works with leading life sciences firms and diagnostic laboratories to accelerate drug development and deliver faster, more predictive diagnostics to patients. PathAI plans to use new capital to enhance offerings to existing partners, drive continuous improvement of its platform, meet market demand, and fund R&D into new tools and medical devices. The company has secured quality management and information security certifications and publicly noted partnerships with Bristol-Myers Squibb and Novartis. Staff headcount grew from 25 to more than 60 over the past year, reflecting investments in machine learning, product development, regulatory affairs, and scientific program management. Headquartered in Boston, PathAI emphasizes scaling its solutions globally to improve patient diagnosis and treatment.

Total raised

$300M

Funding rounds

4

Latest round

Series C

Latest activity

May 2021